Active Ingredient History
Medroxyprogesterone acetate (INN, USAN, BAN), also known as 17α-hydroxy-6α-methylprogesterone acetate, and commonly abbreviated as MPA, is a steroidal progestin, a synthetic variant of the human hormone progesterone. Medroxyprogesterone acetate (MPA) administered orally or parenterally in the recommended doses to women with adequate endogenous estrogen, transforms proliferative into secretory endometrium. Androgenic and anabolic effects have been noted, but the drug is apparently devoid of significant estrogenic activity. While parenterally administered MPA inhibits gonadotropin production, which in turn prevents follicular maturation and ovulation, available data indicate that this does not occur when the usually recommended oral dosage is given as single daily doses. MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is normally being administered is MPA and not MP. Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens. Progestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Amenorrhea (approved 1959)
Endometrial Hyperplasia (approved 1959)
Uterine Hemorrhage (approved 1959)
Alveolar Bone Loss (Phase 4)
Alzheimer Disease (Phase 2/Phase 3)
Art (Phase 4)
Bone Density (Phase 4)
Bone Diseases (Phase 4)
Breast Neoplasms (Phase 4)
Carcinoma, Renal Cell (Phase 3)
Cardiovascular Diseases (Phase 4)
Chlamydia Infections (Phase 4)
Contraception (Phase 4)
Contraception Behavior (Early Phase 1)
Contraception, Postcoital (Early Phase 1)
Coronary Artery Disease (Phase 3)
Coronary Disease (Phase 3)
Depression, Postpartum (Phase 4)
Diabetes Mellitus (Phase 3)
Endometrial Hyperplasia (Phase 4)
Endometrial Neoplasms (Phase 4)
Endometriosis (Phase 4)
Estrogens (Phase 4)
Fertilization in Vitro (Phase 4)
Healthy Volunteers (Phase 2/Phase 3)
Heart Diseases (Phase 3)
HIV (Phase 4)
HIV Infections (Phase 2)
Hot Flashes (Phase 3)
Hypercholesterolemia (Phase 3)
Hypertension (Phase 3)
Infertility (Phase 4)
Inflammation (Phase 4)
Kidney Diseases (Phase 4)
Kidney Neoplasms (Phase 3)
Lactation (Phase 4)
Lactation Disorders (Phase 4)
Lupus Erythematosus, Systemic (Phase 3)
Menopause (Phase 4)
Menorrhagia (Phase 3)
Metrorrhagia (Phase 4)
Myelodysplastic Syndromes (Phase 2)
Myocardial Ischemia (Phase 3)
Neisseriaceae Infections (Phase 4)
Osteoporosis (Phase 4)
Osteoporosis, Postmenopausal (Phase 1)
Ovulation (Phase 4)
Pain (Phase 2)
Polycystic Ovary Syndrome (Phase 3)
Postmenopause (Phase 4)
Pregnancy (Early Phase 1)
Pregnancy Complications (Early Phase 1)
Primary Ovarian Insufficiency (Phase 2)
Prostatic Neoplasms (Phase 3)
Quality of Life (Phase 3)
Sleep Apnea Syndromes (Phase 2/Phase 3)
Smoking (Phase 4)
Smoking Cessation (Phase 4)
Smoking Reduction (Phase 4)
Thrombosis (Phase 3)
Tuberculosis (Phase 2)
Turner Syndrome (Phase 3)
Uterine Diseases (Phase 4)
Uterine Hemorrhage (Phase 3)
Uterine Neoplasms (Phase 2)
Vasomotor System (Phase 2)
Weight Gain (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
